Suba Krishnan

4.2k total citations · 3 hit papers
21 papers, 2.6k citations indexed

About

Suba Krishnan is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Suba Krishnan has authored 21 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Hematology and 7 papers in Genetics. Recurrent topics in Suba Krishnan's work include Cancer Immunotherapy and Biomarkers (7 papers), Hemoglobinopathies and Related Disorders (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Suba Krishnan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Hemoglobinopathies and Related Disorders (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Suba Krishnan collaborates with scholars based in United States, Italy and Canada. Suba Krishnan's co-authors include Katherine A. Hajjar, Arlene O. Siefker‐Radtke, Daniel A. Vaena, Sumanta K. Pal, Elizabeth R. Plimack, José Ángel Arranz, Marc‐Oliver Grimm, Ari David Baron, Alexandre Lambert and Alex Azrilevich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Suba Krishnan

21 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

2020 335 citations Sarina A. Piha‐Paul, Do‐Youn Oh et al. International Journal of Cancer profile →
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →

Peers

Suba Krishnan

ONCOL

SURGE

IMMUN

PRM

Alexandre Lambert United States

Jonathan Juco United States

Susanna Cappia Italy

Wolfgang Eisterer Austria

Thomas Powles United Kingdom

Gregg Fine United States

Christian Meyer zum Büschenfelde Germany

Joan Somja Belgium

Patricia Marinello United States

Jacques Bosq France

Alexandre Lambert United States

Suba Krishnan

1.8k ×1.0

ONCOL

1.0k ×0.8

SURGE

579 ×0.9

IMMUN

702 ×1.5

PRM

372 ×0.8

Citations per year, relative to Suba Krishnan Suba Krishnan (= 1×) peers Alexandre Lambert

Countries citing papers authored by Suba Krishnan

Since Specialization

Citations

This map shows the geographic impact of Suba Krishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suba Krishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suba Krishnan more than expected).

Fields of papers citing papers by Suba Krishnan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suba Krishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suba Krishnan. The network helps show where Suba Krishnan may publish in the future.

Co-authorship network of co-authors of Suba Krishnan

This figure shows the co-authorship network connecting the top 25 collaborators of Suba Krishnan. A scholar is included among the top collaborators of Suba Krishnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suba Krishnan. Suba Krishnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sonpavde, Guru, Justin Call, Gerald S. Falchook, et al.. (2024). A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3191–TPS3191. 2 indexed citations

McKean, Meredith, Ecaterina E. Dumbrava, Omid Hamid, et al.. (2022). Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2651–2651. 2 indexed citations

Reardon, David A., Tae Min Kim, Jean‐Sébastien Frenel, et al.. (2021). Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial. Cancer. 127(10). 1620–1629. 87 indexed citations

Piha‐Paul, Sarina A., Do‐Youn Oh, Makoto Ueno, et al.. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies. International Journal of Cancer. 147(8). 2190–2198. 335 indexed citations breakdown →

Hyman, David M., Andrew Hendifar, Hyun Cheol Chung, et al.. (2019). Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study. Cancer Research. 79(13_Supplement). CT229–CT229. 2 indexed citations

Bang, Yung‐Jue, Makoto Ueno, David Malka, et al.. (2019). Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. Journal of Clinical Oncology. 37(15_suppl). 4079–4079. 92 indexed citations

Sharma, Padmanee, Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 18(3). 312–322. 1203 indexed citations breakdown →

Callahan, Margaret K., Harriet M. Kluger, Michael A. Postow, et al.. (2017). Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of Clinical Oncology. 36(4). 391–398. 137 indexed citations

Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →

10.

Sznol, Mario, Harriet M. Kluger, Margaret K. Callahan, et al.. (2014). Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).. Journal of Clinical Oncology. 32(15_suppl). LBA9003–LBA9003. 118 indexed citations

11.

Setty, Yamaja, Nigel S. Key, A. Koneti Rao, et al.. (2012). Tissue factor‐positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. British Journal of Haematology. 157(3). 370–380. 56 indexed citations

12.

Quinn, Charles T., Marie J. Stuart, Karen Kesler, et al.. (2011). Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology. 155(2). 263–267. 28 indexed citations

13.

Setty, Yamaja, et al.. (2010). Tissue Factor Procoagulant Activity and Coagulation Activation In Sickle Cell Disease: Relationship with Biomarkers of Hemolysis and Inflammation. Blood. 116(21). 4210–4210. 2 indexed citations

14.

Krishnan, Suba, et al.. (2009). Increased levels of the inflammatory biomarker C‐reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. British Journal of Haematology. 148(5). 797–804. 84 indexed citations

15.

Setty, Yamaja, et al.. (2009). Imbalance in Arachidonic Acid to Docosahexaenoic Acid Ratios in the Sickle Red Cell Is Associated with Inflammation.. Blood. 114(22). 2566–2566. 1 indexed citations

16.

Krishnan, Suba, et al.. (2008). Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thrombosis Research. 122(4). 455–458. 24 indexed citations

17.

Krishnan, Suba, et al.. (2003). Annexin II-mediated plasmin generation activates TGF-β3 during epithelial–mesenchymal transformation in the developing avian heart. Developmental Biology. 265(1). 140–154. 17 indexed citations

18.

Krishnan, Suba, et al.. (1999). An overview of quality control practices in Ontario with particular reference to cholesterol analysis. Clinical Biochemistry. 32(2). 93–99. 3 indexed citations

19.

Hajjar, Katherine A. & Suba Krishnan. (1999). Annexin II. Trends in Cardiovascular Medicine. 9(5). 128–138. 134 indexed citations

20.

Henderson, A R, et al.. (1998). Proficiency testing of creatine kinase and creatine kinase-2: the experience of the Ontario Laboratory Proficiency Testing Program. Clinical Chemistry. 44(1). 124–133. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact